Viewing Company CVS Health Corp | StockChase
stockchase picture

Compiling comments that experts make about stocks while on public TV.

CVS Health Corp Stock Symbol: CVS-N

Notes:

retail drug store chain

Last Price Recorded: $76.6400 on 2017-05-26

Globe 5 day average
Google Discussions (view only)
yahoo discussion
Bloomberg
Date Signal Expert Opinion Price
2017-05-19 COMMENT John Petrides

He likes this a lot. Trading at 13X earnings, a discount to its major competitor Walgreens (WBA-Q) at 16X. Trading at a big discount to the market. You get a really nice dividend. The company buys back a lot of stock. Also, has Caremark, the pharmacy management business, which is under a bit of pressure because of drug prices. You really have a diversified business model between the PBM side and the store side. Long-term fundamentals on the healthcare business are very favourable, where you have an aging and growing population. This is very attractive.


Price:
$76.320
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
Unknown
2017-05-17 COMMENT David Baskin

The problem they’ve run into is a controversy about pharmaceutical benefits management, and what is going to happen with the intermediary companies. The problem is that Trump and some congressmen feel that what they are doing raises the price of drugs for other people. In the meantime, they are running a huge chain of drugstores, and increasingly, home-based medical care. He thinks the pharmaceutical benefits thing will blow over. He is still a buyer.


Price:
$76.330
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2017-05-01 TOP PICK Paul Harris, CFA

A pharmaceutical company, long-term care company and a consulting services company. Has a free cash flow yield of about 7%. The CVS business is a good solid business with lots of cash. There are only 2 competitors in the US drug store business. There has been a little slippage on same-store sales, but feels they have straightened that out. Their long-term care business is really important, and he thinks there is good growth here. Thinks the stock is worth around $95. Yield of 2.4%. (Analysts’ price target is $87.50.)


Price:
$81.960
Subject:
GLOBAL
Bias:
OPTIMISTIC
Owned:
Yes
2017-04-27 DON'T BUY Mohsin Bashir

He used to believe it was worth hanging onto, but he has moved on.  It is stuck in limbo.  The question is what the margins will look like.


Price:
$82.790
Subject:
NORTH AMERICAN - LARGE
Bias:
CAUTIOUS
Owned:
No
2017-04-19 HOLD Bruce Murray

This had issues when they became an insurance company and a drugstore. They also went into the UK and bought Boots. The conflict of interest between being a healthcare provider and trying to get people to go to your store has hit it. A solid business and is not going away.


Price:
$77.830
Subject:
LARGE CAP GROWTH & DIVIDENDS
Bias:
UNKNOWN
Owned:
No
2017-04-13 TOP PICK Paul Harris, CFA

A kind of integrated health care company. It is a pharmacy and has a long-term care business. Trades at 13X earnings. The stock has pulled off from its highs. Has a free cash flow yield of about 7%. They’ve had some issues on the same store sales side over the last while, and he thinks that is stabilizing. On the healthcare side, they need to make a few more acquisitions. Thinks the intrinsic value is somewhere between $90 and $95. Dividend yield of 2.6%. (Analysts’ price target is $87.50.)


Price:
$77.960
Subject:
GLOBAL
Bias:
UNKNOWN
Owned:
Yes
2017-04-12 PAST TOP PICK Christine Poole

(A Top Pick March 10/16. Down 20%.) This is the leading drugstore in the US on the retail side. Last fall, their scripts got excluded from the PBM networks, so they are losing some prescription volumes, which is a short-term negative. Earnings are going to be somewhat flat this year, but they feel they can continue growing earnings at a 10% rate past 2017. She likes the space. Their competitor, Walgreens (WBA-Q), is in the process of acquiring Rite Aid (RAD-N), so expects CVS will pick up some stores at that time. Trading at about 2 multiples discount to Walgreens because of their near term earnings stumble. Thinks the disappointment is already priced into the stock.


Price:
$77.960
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
2017-04-06 DON'T BUY Cameron Hurst

There is retail and pharma benefits managment.  It does not meet his criteria.  It has not broken out.  The PBM is facing pressure.  Their fees are a percent, which is riskier.  Their fundamentals don’t line up.  There are better places to put money.


Price:
$77.010
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Unknown
2017-03-13 HOLD Matt Kacur

A really great company with a successful long-term track record, which should continue in the future. A couple of things have taken the stock down. Walgreens (WBA-Q) had a new deal, which was going to eat into the market share, so of course the stock took a bit of a hit. Also, there is the potential legislation on repricing of drugs. The whole drug chain is probably susceptible to some repricing. Thinks these 2 things are already priced in.


Price:
$80.440
Subject:
NORTH AMERICAN
Bias:
CAUTIOUS
Owned:
Unknown
2017-03-01 COMMENT John Burke

A big fan. The healthcare sector is cheap. This one has a tremendous free cash flow yield. They pretty much have the market all to themselves, and he likes markets where there aren’t very many competitors. (See Top Picks.)


Price:
$80.700
Subject:
US EQUITIES
Bias:
UNKNOWN
Owned:
Yes
2017-02-16 TOP PICK David Baskin

They have a huge platform of pharmacies in the US, pharma benefits management and home healthcare.  The baby boomer generation is not going to suddenly not need their pills any more.  It is very cheap right now.  (Analysts’ target: $86.34).


Price:
$79.450
Subject:
NORTH AMERICAN - LARGE
Bias:
SELECTIVE
Owned:
Yes
2017-02-08 COMMENT Cameron Hurst

Valuation has come back into line. They have retail which had some good comps for a while, but people are not spending as much in the store right now. Also, they are losing share to Walgreens (WBA-Q).


Price:
$77.030
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
Unknown
2017-01-26 PAST TOP PICK Gordon Reid

(Top Pick Jan 21/16, Down 13.41%) Many of the comments he made about WBA-N apply here. People are waiting to see the dust settle.  These companies continue to do well.  They are a good place to be patient.  Just because you are not rewarded on price does not mean you are happy with the fundamentals.  Trade less rather than more.


Price:
$79.330
Subject:
US EQUITIES
Bias:
BULLISH
Owned:
Yes
2017-01-20 TOP PICK Michael Simpson, CFA

The 2nd largest drugstore in the US, but also a PBM, (Pharmacy Benefit Manager). PBM’s are a little misunderstood in the US. They were set up because corporations didn’t want to deal with managing employees’ drug benefits. PBM’s actually save companies money. Depending on the contract, they can pass through 85%-100% of their money. CVS is going to buy back about 5 billion of shares. Good dividend growth rate and free cash flow. This is trading much lower than the market. Dividend yield of 2.44%. (Analysts’ price target is $88.74.)


Price:
$81.560
Subject:
NORTH AMERICAN DIVIDENDS
Bias:
UNKNOWN
Owned:
Yes
2017-01-11 HOLD Christine Poole

This pulled back because it had to reduce its earnings guidance for this upcoming year. They had been guiding for 10%-14% growth for the next few years, and have had to reduce that to 10% going forward. This is because their drug retail side has been excluded in certain pharmacy networks. The valuation is very attractive at about 13 or 14 times forward earnings. A well-managed company.


Price:
$82.770
Subject:
NORTH AMERICAN - LARGE
Bias:
UNKNOWN
Owned:
Yes
Showing 1 to 15 of 110 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.